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Objective: Melatonin synthesis and secretion are partly modulated by estrogen and 31 
progesterone. Changes in melatonin concentrations, possibly related to the menopausal 32 
transition, may be associated with climacteric mood, sleep and vasomotor symptoms. The 33 
aims of this study were to compare the serum concentrations of melatonin in perimenopausal 34 
and postmenopausal women, and to evaluate its influence on mood, sleep, vasomotor 35 
symptoms and quality of life. Methods: We analyzed data of 17 perimenopausal (43-51 36 
years) and 18 postmenopausal (58-71 years) healthy women who participated in a prospective 37 
study. During the study night (21:00-09:00 hr) serum melatonin was sampled at 20-minute 38 
(21:00-24:00 hr; 06:00-09:00 hr) and one-hour (24:00-06:00 hr) intervals. Questionnaires 39 
were used to assess depression (Beck Depression Inventory, BDI), anxiety (State-Trait 40 
Anxiety Inventory, STAI), insomnia and sleepiness (Basic Nordic Sleep Questionnaire, 41 
BNSQ), subjective sleep quality, vasomotor symptoms, and the quality of life (EuroQoL). 42 
Results: Postmenopausal women had lower nighttime serum melatonin concentrations than 43 
perimenopausal women. The duration of melatonin secretion tended to be shorter in 44 
postmenopause, while the melatonin peak time did not differ. Mean melatonin concentrations 45 
and exposure levels did not correlate with FSH or E2, BMI, BDI, STAI, BNSQ insomnia, 46 
BNSQ sleepiness, subjective sleep, climacteric vasomotor score or the quality of life. In 47 
perimenopause, the later the melatonin peak, the higher the level of anxiety (p=0.022), and the 48 
longer the melatonin secretion, the better the quality of life (p<0.001). Conclusions: 49 
Longitudinal research is needed to better understand the possible contributive role of 50 
menopause on lower melatonin levels. 51 
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Melatonin is a hormone produced primarily by the pineal gland and by the retina, skin and 57 
gastrointestinal tract.1 The synthesis and secretion of melatonin follow a circadian rhythm and 58 
are indirectly regulated by the light/dark cycle, with light having an inhibitory and darkness a 59 
stimulatory effect.2 According to animal and human studies, estrogen and, at a less extent, 60 
progesterone3-6 also contribute to direct and indirect modulation of melatonin synthesis and 61 
secretion. In addition, melatonin concentration is influenced by administration of 62 
gonadotropin-releasing hormone agonists,7,8 and in general, the circulating melatonin 63 
concentrations seem to be high when endogenous estrogen levels are low, like in women 64 
using oral contraception.9 Reciprocally, it has been suggested that melatonin has a 65 
regulatory,10 mostly inhibitory, effect on reproduction, probably by down-regulating the 66 
hypothalamic-pituitary-ovarian axis and modulating estrogen synthesis in peripheral tissues,11 67 
such as in the breast, muscles and adipose tissue. For instance, Voordouw et al.12 found a 68 
reduced ovarian function, decreased luteinizing hormone and estrogen and progesterone levels 69 
after 4-month melatonin (or melatonin-progestin combinations) administration in adult 70 
women. Elevated levels of plasma/serum nocturnal melatonin (concentration, area under 71 
curve AUC, peak amplitude) have also been associated with reproductive malfunctions13 such 72 
as amenorrhea in women 7,14and hypogonadism in men.15  73 
Although the peak serum melatonin concentrations, as well as the total amount of urinary 74 
melatonin, decrease physiologically with age both in men and women,16,17 probably due to 75 
pineal aging, it is possible that in women the mean nocturnal melatonin concentrations, as 76 
well as the melatonin peak time, the amplitude and duration of melatonin secretion vary 77 
during the menopausal transition in relation to changes in gonadal hormone levels. However, 78 




Because of this possible reciprocal relationship between melatonin and gonadal hormones, 80 
and since long-term administration of melatonin was found to partly improve the quality of 81 
life (with regard to the physical domain) in perimenopausal women,21 it is possible to 82 
hypothesize that melatonin may also contribute to mitigate other symptoms associated with 83 
the perimenopausal hormonal fluctuations. Among others, depressive and anxiety symptoms 84 
and disorders are common during the perimenopause.22-24 Impaired sleep quality is also 85 
common during the menopausal transition and in postmenopause.25-29 Melatonin is known to 86 
influence mood and sleep. In fact, even with some inconsistencies, melatonin secretion seems 87 
to be lower in individuals having depression,30-35 and melatonin or melatonin receptor 88 
agonists have antidepressants, anxiolytic and sleep-promoting effects.36-39 It is therefore 89 
plausible that changes in melatonin concentrations related to both aging and transition to 90 
menopause may at least partly explain depressive, anxiety and sleep symptoms as well as 91 
climacteric vasomotor symptoms, typically experienced by women during perimenopause and 92 
postmenopause. 93 
Given the general lack of data on the association between melatonin concentration and 94 
secretion pattern and the transition to menopause, the aim of this work was to describe the 95 
melatonin levels in perimenopausal and postmenopausal women. We hypothesized that 96 
postmenopausal women have lower mean nighttime serum melatonin concentrations, as well 97 
as lower melatonin exposure levels and shorter duration of nighttime secretion than 98 
perimenopausal women. Our further aim was to evaluate the relationship between melatonin 99 
levels and depressive, anxiety, sleep and vasomotor symptoms, as well as quality of life in 100 
perimenopausal and postmenopausal women. We hypothesized that low melatonin 101 
concentrations and exposure levels, and shorter duration of secretion associate with more 102 






The current study was part of a larger survey evaluating the effects of menopause on sleep and 106 
cognition. The women were recruited through advertisements in the local newspapers in the area 107 
of Turku, Finland; 17 of them were perimenopausal (aged 43-51 years), and 18 postmenopausal 108 
(aged 58-71 years). Perimenopausal status was defined by the serum follicle stimulating hormone 109 
(FSH) level (< 23 IU/mL) and an ongoing regular or irregular menstrual cycle. Postmenopause 110 
was determined by age ( ≥ 58 years) and at least 12 months of amenorrhea. 111 
The exclusion criteria included presence of a mental, cardiovascular (with the exception of 112 
drug-treated balanced hypertension), endocrine (with the exception of drug-treated balanced 113 
hyperlipidemia), pulmonary, neurological or specific sleep disorder; malignancies; alcohol 114 
abuse, smoking, excessive caffeine intake (>5 cups per day) and use of other substances that 115 
are known to affect the central nervous system. In addition, women suffering from other 116 
conditions possibly affecting sleep (e.g. fibromyalgia and anemia) were excluded. All women 117 
had normal levels of blood hemoglobin, leukocytes, thrombocytes and serum thyrotropin. One 118 
perimenopausal woman and 13 postmenopausal women had previously used hormone therapy 119 
(HT), and a washout period of at least 12 months was required. More details about the data 120 
collection and study design have already been described elsewhere.40 After receiving oral and 121 
written information, all participants gave written informed consent. The study was approved 122 
by the Ethics Committees of Turku University Hospital and of University of Turku, Finland. 123 
The participants kept a sleep diary during the three weeks before and one week after the study 124 
to verify their sleep-wake rhythms. All women had regular sleep-wake schedules (from 22:00-125 
23:00 hr to 06:00-07:00 hr). Travelling abroad, as well as use of alcohol and caffeine was 126 
prohibited one week before and during the study. Coffee-drinkers were provided with 127 




The blood samples were collected all throughout the year; in detail, 13 of the 17 129 
perimenopausal women, and 10 of the 18 postmenopausal women were studied during winter 130 
time (October to March). The participants spent one adaptation night (from 19:30 to 08:00 hr; 131 
lights-off at 23:00, lights-on at 07:00 hr) in the sleep laboratory. In the following morning, a 132 
blood sample was taken for baseline serum FSH and estradiol (E2) measurements. On the 133 
following evening, the women returned to the laboratory at 19:30 hr for the baseline sleep 134 
recording (lights-off at 23:00, lights-on at 07:00 hr), which was repeated also through the 135 
third night. During the night only red light was allowed for illumination if needed. Therefore, 136 
during the study period the participants spent their time inside a building, in a dark room 137 
without windows, with strictly controlled nighttime illumination levels; this has limited the 138 
possible influence of different photoperiods in different subjects. The study was performed by 139 
similar timetable in all subjects and food was provided by the sleep laboratory.  140 
On the evening before the third night an indwelling catheter was inserted into a forearm vein 141 
to permit a 24-hour blood sampling at 20-minute intervals, starting from 21:00 hr. At night 142 
(from 21:00 to 07:00 hr) the catheter was connected to a plastic tube extending into an 143 
adjacent room: this allowed repeated blood sampling without disturbing the woman's sleep. 144 
The catheter was kept patent with a slow heparinized saline infusion. Thus, melatonin 145 
measurements were available for 20-minute interval samples between 21:00 and midnight, 146 
and from 06:00 to 09:00 hr; measurements on one-hour interval samples were available 147 
between midnight and 06:00 hr. All perimenopausal women were examined in the beginning 148 
of their menstrual cycle (i.e., in the follicular phase). 149 
The blood samples were drawn into EDTA tubes and placed in the refrigerator for 20 min. 150 
Thereafter, they were centrifuged to separate serum, which was frozen at 70° C until assayed. 151 
The inter-assay coefficients of variation were 2.3% for FSH at a concentration of 44.8 IU/l 152 




IU/l and 0.05 nmol/l respectively. For melatonin analyses the serum samples were first 154 
extracted with chloroform and then assayed by radioimmunoassay with an iodinated 155 
melatonin tracer and a melatonin-specific antiserum.41 The lowest detectable concentration by 156 
the method was 1.3 pg/ml (5.7 pmol/l), and the intra-assay and inter-assay coefficients of 157 
variation were from 6.7 to 9.5% and from 9.8 to 12.5%, respectively. 158 
The following melatonin indicators were derived: 1. the mean nighttime serum melatonin 159 
concentration from lights-off (at 23:00 hr) to lights-on (at 07:00 hr); 2. the range and mean of 160 
maximum and minimum levels of nighttime serum melatonin concentration (from lights-off to 161 
lights-on); 3. the nighttime melatonin exposure level: after the interpolation of melatonin 162 
exposure level curve, the area under melatonin exposure curve (AUC, from lights-off to 163 
lights-on) was calculated for each individual, and the mean, quartile and median values of 164 
melatonin exposure levels were calculated; 4. the duration of nighttime melatonin secretion: 165 
the total amount of time (in hours) when serum melatonin levels (circulating melatonin) were 166 
≥10 pg/ml, where 10 pg/ml is the usual threshold for melatonin onset;42,43 5. the melatonin 167 
peak time: the clock time of the peak of melatonin secretion; and 6. the time from lights off to 168 
melatonin peak time (in hours). 169 
 170 
Questionnaires 171 
Depressive symptoms during the past four weeks were evaluated with the Beck Depression 172 
Inventory (BDI, a sum score, with the range of 0-63),44 and current anxiety level with the 173 
State-Trait Anxiety Inventory (STAI, a sum score, with the range of 20-80).45 Insomnia (a 174 
sum score, with the range of 5-25) and sleepiness (a sum score, with the range of 5-25) during 175 
the past three months were evaluated using the Basic Nordic Sleep Questionnaire (BNSQ),46 176 
with lower score referring to better sleep (i.e., low levels of sleeping problems and sleepiness; 177 




insomnia and sleepiness of the BNSQ). In addition, the subjective sleep score (a sum score 179 
with the range of 6-20) of the preceding blood-sampling night in the laboratory was assessed 180 
in the morning by questions on sleep quality, sleep efficiency, sleep latency, number of 181 
awakenings, too early morning awakening and morning tiredness, with lower number 182 
referring to better sleep or to a low level of sleeping problems (see Appendix 2, Supplemental 183 
Digital Content 2, which reports the questions concerning the sleep of preceding night used to 184 
calculate the subjective sleep score). Climacteric vasomotor symptoms were scored with two 185 
questions on the past six months (night sweats and hot flashes). The frequency of the 186 
symptoms (a sum score, with the range of 2-8) was determined on the following four-point 187 
scale: one (“seldom or never”), two (“approximately once a month”), three (“approximately 188 
once a week”), four (“almost every day”). The current quality of life (an index score, with the 189 
range of from -0.011 to +1) was assessed using the EuroQoL quality of life questionnaire 190 
(EQ-5D) and the EQ-5D visual analogy scale (VAS, a scale score, with the range of 1-100).47 191 
The EQ-5D index was calculated through a specific algorithm which considers a weight for 192 
each dimension.48 The questionnaires were administered during the day after the blood 193 
sampling. 194 
 195 
Statistical analysis 196 
After testing for normality of the distribution (the Kolmogorov–Smirnov test), bivariate 197 
analyses were calculated to study the differences between perimenopausal and 198 
postmenopausal women using Student's t-test for comparison of the mean values. A p-value 199 
of <0.05 was considered significant. The mean, maximum and minimum levels of nighttime 200 
serum melatonin concentrations, the mean nighttime melatonin exposure level, the duration of 201 
nighttime melatonin secretion and the melatonin peak time in perimenopausal vs. 202 




Bivariate Pearson correlation analyses were performed separately in perimenopausal women 204 
and in postmenopausal women between nighttime serum melatonin concentrations, melatonin 205 
exposure level, duration of nighttime melatonin secretion and the time from lights off to 206 
melatonin peak, vs. independent variables including FSH, E2, body-mass index (BMI), BDI, 207 
STAI, BNSQ insomnia, BNSQ sleepiness, subjective sleep score, climacteric vasomotor 208 
symptom score and quality of life (EQ-5D index and EQ-5D VAS). Interaction analyses were 209 
performed to test the associations between nighttime melatonin exposure (AUC) and, 210 
alternatively, each of the independent variables that differed (or tended to differ) between 211 
perimenopausal and postmenopausal women (i.e., FSH levels, E2 levels, BMI, BDI, BNSQ 212 
insomnia and climacteric vasomotor scores). Menopausal status was entered in each model as 213 
a controlling variable. The statistical analyses were performed using the SPSS/PASW 214 
software version 18.0 (SPSS Inc., Chicago, IL, USA) and the R program.49 215 
 216 
Results 217 
The basic characteristics of the participants are described in Table 1. As determined, 218 
perimenopausal women were younger and had lower FSH levels and higher E2 levels than 219 
postmenopausal women. In addition, perimenopausal women had lower BMI and less 220 
climacteric vasomotor symptoms. A tendency towards lower BDI and BNSQ insomnia scores 221 
was found in perimenopausal women. No differences were found in respect to anxiety scores 222 
on the STAI, sleepiness scores on the BNSQ or subjective sleep questionnaire, or the quality 223 
of life on the EQ-5D index or EQ-5D VAS. 224 
Data on melatonin levels was available for 17 perimenopausal and 17 postmenopausal women 225 
(data missing from one postmenopausal woman). Values of melatonin indicators in 226 
perimenopausal and postmenopausal women are reported in Table 2. Mean nighttime serum 227 




melatonin exposure level (AUC) were lower in postmenopausal compared with 229 
perimenopausal women (Table 2 and Figure 1). Although the melatonin peak time did not 230 
differ between the two groups, the duration of the nighttime melatonin secretion (serum level 231 
≥10 pg/ml; 43.1 pmol/l) approached the significant level for a longer duration in 232 
perimenopausal women than in postmenopausal women (6 h 47 min vs. 6 h 22 min, 233 
respectively; p=0.058). 234 
The mean nighttime melatonin concentration and age did not correlate. Further, mean 235 
nighttime serum melatonin concentration did not correlate with FSH levels or E2 levels, BMI, 236 
BDI, STAI, BNSQ insomnia, BNSQ sleepiness, subjective sleep of the preceding night, 237 
climacteric vasomotor score or the quality of life (EQ-5D score and EQ-VAS) either in 238 
perimenopausal or postmenopausal women. No correlations were found between nighttime 239 
melatonin exposure level (AUC) and any of the independent variables either in 240 
perimenopausal or postmenopausal women. In the perimenopausal group, the time from lights 241 
off to melatonin peak correlated with scores on the STAI (r=0.55, p=0.022), i.e., the later the 242 
melatonin peak, the higher the anxiety level. In addition, the duration of nighttime melatonin 243 
secretion (serum levels ≥10 pg/ml; 43.1 pmol/l) correlated with the EQ5D-VAS scores 244 
(r=0.74; p<0.001), i.e. the longer the duration of nighttime melatonin secretion, the better the 245 
quality of life. No correlations were found in the postmenopausal group. 246 
In interaction analyses, no association was found between nighttime melatonin exposure level 247 
(AUC) and FSH or E2 levels, BMI, BDI, BNSQ insomnia or climacteric vasomotor scores 248 
after controlling for the menopausal status.  249 
 250 
Discussion 251 
From these results using serial blood draws, we are among the first to observe that as 252 




melatonin concentrations at each time point. However, the nighttime pattern of rise and fall in 254 
melatonin levels, including the melatonin peak time was similar for both groups. Although not 255 
reaching statistical significance, the nighttime duration of melatonin secretion (the circulating 256 
melatonin concentrations equal to or more than 10 pg/ml) was longer in the perimenopausal 257 
women. Postmenopausal women had more depressive, insomnia and climacteric vasomotor 258 
symptoms than perimenopausal women, but there was no evidence that these symptoms were 259 
related to the melatonin levels for either group. 260 
Our findings of lower nighttime melatonin concentrations in postmenopausal women may be 261 
a reflection of the well-known age-related decrease of melatonin levels,16,17 where the 262 
transition into menopause may be itself considered as a dimension of aging, in specific of the 263 
hypothalamus-pituitary-ovarian system. In this respect, it is possible that the menopause-264 
related hormonal alterations, or the accompanying mood, sleep and vasomotor symptoms, 265 
may modulate melatonin activity, e.g. by accelerating its reduction. On the other hand, it is 266 
also possible that the age-related changes in melatonin, whether or not attributable to the 267 
hypothalamus-pituitary-ovarian-axis-related hormone changes, contribute themselves to the 268 
modulation of ovarian hormone fluctuations, or to the menopause-associated mood, sleep and 269 
vasomotor symptoms. 270 
To date, only a few works have focused on this issue. In the study of Okatani et al.20 the 271 
nighttime serum melatonin concentration (measured via 2-hour interval samples between 272 
20.00 and 08:00 hr) was higher in the oldest premenopausal women (aged 46 to 50 years, i.e. 273 
likely perimenopausal) compared to younger premenopausal women with or without 274 
oophorectomy. Additionally, they found that nocturnal melatonin concentration and secretion 275 
decreased steeply in the first 15 years since the beginning of menopause, and continued to 276 
decrease more gradually thereafter. In that study reproductive state was determined on the 277 




them into premenopausal and postmenopausal groups on the basis of their menstrual records, 279 
and thereafter into six further age groups. Nocturnal (20.00-08.00 hr) urinary excretion of 280 
melatonin and morning (09.00 hr) serum melatonin were measured. Urinary melatonin levels 281 
were found to decline during the menopausal transition, the most significantly in women aged 282 
40-44 years, followed by those over 50 years; also, the serum morning melatonin levels 283 
tended to be lower in women aged 60 years and over compared to women younger than 40 284 
years. Keeping in mind the different age ranges of the participants, as well as the different 285 
melatonin sampling (nocturnal urinary and morning serum samples in the Vakkuri et al. 286 
study,19 vs. serial nocturnal serum samples in our current work), these results are in line with 287 
our findings of decreased melatonin concentration in postmenopause. Since the drop in 288 
melatonin levels was most notable far before menopausal age, the authors concluded that it 289 
could be permissively linked to the initiation of menopause. Frequently, changes in the 290 
hypothalamus-pituitary-ovarian function start several years before the actual cessation of 291 
menstrual periods, i.e. at the age where the drop in melatonin level was more evident. Further, 292 
Vakkuri et al.19 reported a negative correlation between urinary melatonin and serum FSH. 293 
Fernandez et al.18 found the lowest values of morning serum (but not urinary) melatonin 294 
levels in postmenopausal women. Moreover, they found no correlation between melatonin 295 
and FSH, E2 or progesterone levels during the perimenopausal period, but a negative 296 
correlation between FSH and melatonin levels in the postmenopausal women. We did not find 297 
any association between melatonin and FSH or E2 levels in either perimenopausal or 298 
postmenopausal women. A plausible reason for the lack of such correlation was a 299 
considerable inter-individual variation in melatonin secretion in our study. However, it may 300 
not be ignored that we used the mean value of repeated nocturnal serum samples, instead of 301 
an overnight urinary sample as in the study of Vakkuri et al.19 or a single morning serum 302 




sampling technique is among the most practical ones for the assessment of melatonin 304 
secretion, given its limited possibility of repeated samples, it may lack in precision. Saliva 305 
sampling is also a practical and reliable technique, which allows repeated samples; however, 306 
it can hardly be used for overnight assessment. On the contrary, repeated blood samples can 307 
be more easily taken at frequent intervals during night without or with limited sleep 308 
disruption. In addition, the levels of melatonin are higher in the plasma than in the saliva, thus 309 
implying a better resolution and sensitivity. In detail, overnight blood sampling at frequent 310 
intervals seems to be the most informative technique for the assessment of melatonin 311 
profile.50  312 
Our results also suggest that the nighttime pattern of rise and fall in melatonin levels, 313 
including the melatonin peak time, does not significantly differ between perimenopausal and 314 
postmenopausal women. This finding is in contrast with the earlier report of Walters et al.51 315 
on the advanced phase of melatonin secretion in postmenopausal compared with 316 
premenopausal women during one-night sleep deprivation. However, even though in the same 317 
study the melatonin onset was found to precede the onset of subjective sleepiness equally in 318 
the premenopausal and postmenopausal women, the time between the melatonin onset and 319 
that of sleepiness was longer in postmenopausal than premenopausal women.51 Possible 320 
explanations for these different outcomes may be the different study designs, since Walters et 321 
al.51 assessed salivary melatonin from samples collected hourly for 22 hours during sleep 322 
deprivation under constant routine conditions, and studied younger groups (premenopausal 323 
aged 38-46 years, postmenopausal aged 53-57 years), whereas we used repeated serum 324 
samples and older study groups (perimenopausal aged 43-51 years, postmenopausal aged 58-325 
71 years) in normal sleeping condition.  326 
Melatonin concentration and secretion pattern seemed not to be related to climacteric 327 




expected, postmenopausal women had more climacteric vasomotor symptoms than 329 
perimenopausal women. They also had a higher BMI, which is known to increase with the 330 
transition to menopause, even with small differences according to the type of menopause.52 It 331 
is possible that, besides other known factors such as changes in estrogen and FSH levels, the 332 
menopause- and age-related changes in melatonin levels also contribute to these symptoms 333 
and body changes in postmenopausal women. A recent animal study showed that 334 
administration of melatonin was more effective than estrogen therapy in reversing the 335 
glycemic and lipid dysregulation as well as in restoring the increased BMI after the 336 
ovariectomy.53 According to another study administration of melatonin to perimenopausal and 337 
postmenopausal women led to a tendency of reduction in climacteric symptoms.54 However, 338 
other studies did not support these results.55,56 Our correlation and interaction analyses did not 339 
find any association between melatonin and climacteric symptoms or BMI, even after 340 
controlling for the effect of menopausal status. 341 
Also, melatonin concentration and secretion pattern seemed not to be related to depressive 342 
symptoms or sleep disturbances either in perimenopausal or in postmenopausal women. In our 343 
sample, postmenopausal women tended to have more depressive and insomnia symptoms. 344 
Instead, anxiety and the quality of life scores did not differ between perimenopausal and 345 
postmenopausal women. This is in line with the well-known increased risk of mood 346 
symptoms and disorders22 and decrease in sleep quality57-60 during the menopausal transition. 347 
In early (<5 years) versus late (>5 years) postmenopausal women, Hachul et al.61 found more 348 
depression, anxiety and sleepiness among the latter group. In general, it has been reported that 349 
perimenopausal and especially postmenopausal women suffer from subjective sleep problems 350 
more than premenopausal women.57-60 In this respect, a prospective study62 showed that even 351 
after controlling for age and other confounding factors, women had higher odds for both 352 




perimenopause, and even higher odds when transiting to postmenopause. However, perhaps 354 
because of the small sample size, correlation and interaction analyses did not detect any 355 
significant associations between melatonin and BDI or BNSQ insomnia scores. Hence, these 356 
findings do not support our original hypothesis that low melatonin levels associate with 357 
depressive, anxiety or sleep symptoms in postmenopausal women. It is of note that melatonin 358 
levels was associated with other parameters in the perimenopausal group: a delayed peak time 359 
was associated with a higher level of anxiety, while a longer duration of melatonin secretion 360 
was associated with better quality of life. It is possible that higher levels of anxiety postponed 361 
the onset of sleep and subsequently the peak of melatonin secretion, whereas longer durations 362 
of melatonin secretion could improve sleep quality and subsequently the quality of life.  363 
This study was the first one to use repeated serum sampling technique to evaluate the 364 
interrelationship of melatonin secretion and menopausal status. This seems to be the best 365 
technique as assessment of melatonin phase, duration and amplitude are concerned, in 366 
particular when frequent (20-30 minutes) samples are provided.50 Even if the study was not 367 
carried out under constant routine conditions, which would have been the most appropriate 368 
technique, nevertheless the high-frequency collection of serum samples under strictly 369 
controlled sleep laboratory conditions ensured the good quality of the samples in order to 370 
monitor the pattern of melatonin concentrations. In addition, several confounding factors were 371 
effectively ruled out by the accurate exclusion criteria, such as irregular sleep-wake 372 
schedules, the use of HT and other medications, smoking as well as the use of alcohol or 373 
drugs. 374 
The main limitation of our study is a rather small sample size in the context of a convenience 375 
sampling design. This, along with the elevated inter-individual variability in melatonin levels, 376 
may partly explain the absence of any significant correlation between melatonin and FSH or 377 




comparable with that of other studies in the field, and even with this limited sample size, 379 
significant differences in melatonin levels were detected. The study was carried out on a 380 
healthy population, preventing the generalization of the results to populations with common 381 
diseases. Further, some of the women in the perimenopausal group had regular menstruation, 382 
categorizing them as premenopausal. In addition, it must be noticed that mood, sleep and 383 
climacteric symptoms and quality of life were retrospectively assessed with self-reported 384 
questionnaires that covered different timeframes of recall (ranging from current quality of life 385 
to climacteric symptoms in the past six months), being a potential weakness in the 386 
measurement of self-reported data. However, the reliability and validity of most of these 387 
instruments have been tested and found to be reliable.46,63,64 The melatonin sampling took 388 
place throughout the year, likely influencing the results. However, during the visit in the sleep 389 
laboratory the participants spent their time inside the building and the nighttime illumination 390 
levels were strictly controlled. Finally, the cross-sectional design of the study did not allow 391 
any causal conclusions.  392 
 393 
Conclusions 394 
Our results confirm lower nighttime serum melatonin concentrations and exposure levels in 395 
postmenopausal women compared with perimenopausal women, with no difference in 396 
melatonin peak time. There was also a tendency towards longer duration of melatonin 397 
secretion in perimenopausal women. Further research with prospective follow-up studies 398 
during menopausal transition is needed to better understand the nature of these differences. 399 
Changes in melatonin levels were not related to mood, sleep quality, vasomotor symptoms or 400 
quality of life either in perimenopause or postmenopause. This finding needs to be confirmed 401 
in larger studies. Whether the beneficial effect of HT on alleviation of these symptoms in 402 
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